.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
People living with schizophrenia spectrum disorders (SSDs) frequently face severe metabolic challenges. Antipsychotic medications often lead to rapid weight gain and insulin resistance. Consequently, this population suffers from significantly higher morbidity rates compared to the general public. Semaglutide for schizophrenia is emerging as a critical intervention to combat these metabolic side effects.
A recent meta-analysis of three randomized controlled trials examined the impact of semaglutide dosages ranging from 1.0 to 2.0 mg. The results showed that semaglutide significantly reduced body weight by an average of 11.32 kg over 26 to 36 weeks. Additionally, participants experienced a decrease in body mass index (BMI) by 3.58 kg/m². Beyond weight, semaglutide improved glycemic markers, lowering haemoglobin A1c by 0.37% and fasting glucose by 0.54 mmol/L. These findings suggest that GLP-1 receptor agonists provide a robust metabolic lifeline for psychiatric patients.
While the efficacy is clear, clinicians must monitor for gastrointestinal side effects. The analysis revealed that semaglutide was associated with an increased risk of abdominal pain, vomiting, and constipation. Specifically, the risk of constipation was more than three times higher in the treatment group. However, there was no evidence of an increased risk of serious adverse events. Therefore, semaglutide remains a safe and promising adjunctive treatment for metabolic dysfunction in this vulnerable population.
Current evidence supports semaglutide as a viable tool for managing weight in SSD patients. However, the study highlights a lack of data for other agents like tirzepatide. Researchers emphasize the need for larger and longer trials to fully understand long-term safety. Future studies should also explore how these treatments affect different patient subgroups to minimize heterogeneity in clinical outcomes.
Studies show that semaglutide can lead to a weight reduction of over 11 kg in patients with schizophrenia spectrum disorders. This is particularly relevant for those taking second-generation antipsychotics that cause weight gain.
Current meta-analyses suggest no increased risk of serious adverse events. The primary side effects are gastrointestinal, such as nausea, vomiting, and constipation, which are usually mild to moderate.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Semaglutide significantly reduces body weight and HbA1c in patients with schizophrenia spectrum disorders, according to a 2026 systematic review and meta-an...
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
